- ‘Really, Really Messed Up My Life’
- Quick Start to Healthy Weight Loss
- Black Men Can Beat Prostate Cancer
- Health Screenings for Older Black Men
- Healthy Man of the Month for July 2016
- HIV Testing is HIV Prevention
- Your ‘Mental’ Endurance
- Bisexual Health Priorities
- Entertainment CEO DonJuan Clark
- New Drug Helps Men with Melanoma
J&J Invests in Prostate Cancer Tx
African-American men are both more likely to be diagnosed with prostate cancer and to die from prostate cancer than are white men, according to Ohio State University’s Wexner Medical Center. In fact, African-American men may have the highest rate of prostate cancer incidence in the world
Johnson & Johnson said it would pay up to $1 billion for Aragon Pharmaceuticals and its experimental drugs for prostate cancer, to bolster J&J’s role in the field after it acquired another experimental prostate-cancer treatment four years ago that has become a leading brand. Aragon’s lead product, called ARN-509, has potential to help patients whose prostate cancer has not yet spread to other parts of the body, as well as patients whose cancer has spread.
By contrast, J&J’s blockbuster Zytiga treatment, acquired through its $1 billion purchase of Cougar Biotechnology in 2009, was approved in 2011 only for patients whose cancer has already spread. Moreover, although Zytiga has become a blockbuster only two years after being launched, it could face competition from cheaper generics by 2016 in the United States, while ARN-509 will have U.S. marketing exclusivity until 2028, Leerink Swann analyst Danielle Antalffy said.
“We expect that J&J will be able to accelerate ARN-509’s development timeline and expand the depth of clinical programs in order to reach the market ahead of Zytiga’s U.S. patent expiration,” Antalffy said.
Zytiga and ARN-509 are both meant for patients who fail to benefit from treatments that block testosterone, the male hormone that fuels prostate cancer. But the two drugs work differently.ARN-509 has potential to be the most effective treatment for such patients, Antalffy said. And because African-American men have considerably higher incidence rates (234.6 cases per 100,000 African-American men in 2003-2007) than white men (150.4 cases per 100,000 white men in 2003-2007), this is an investment that is definitely timely for black males.
J&J spokeswoman Kellie McLaughlin said late-stage trials will be needed to assess how ARN-509 would be used. But she said the drug and Zytiga potentially could work well when used in combination because of their slightly different mechanisms of action. “They might also be studied to see if they can be used sequentially, with patients first taking ARN-509 and then moving on to Zytiga as their disease progresses,” McLaughlin said.
“Prostate cancer is a key area of focus for us, and we are really excited about ARN-509 and adding it to our portfolio.”
ARN-509, which belongs to a new class of drugs called androgen receptor signaling inhibitors, works in a similar way to Medivation Inc’s already approved Xtandi treatment. But Antalffy said early clinical data suggest ARN-509 has potential to be more potent, and to sidestep seizure risks seen with the Medivation drug.